Royalty Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two investor conferences in June 2021. The first event is the Goldman Sachs Global Healthcare Conference on June 9 at 3:50 p.m. EDT, followed by the Bank of America Napa Biopharma Conference on June 15 at 1:30 p.m. EDT. Interested parties can access webcasts from Royalty Pharma’s “Events” page, with recordings available for at least 30 days. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.

NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June:

• Goldman Sachs Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. EDT
• Bank of America Napa Biopharma Conference on Tuesday, June 15 at 1:30 p.m. EDT

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

 

FAQ

What dates will Royalty Pharma participate in investor conferences?

Royalty Pharma will participate in the Goldman Sachs Global Healthcare Conference on June 9, 2021, and the Bank of America Napa Biopharma Conference on June 15, 2021.

What time is the Goldman Sachs Global Healthcare Conference for RPRX?

The Goldman Sachs Global Healthcare Conference for Royalty Pharma (RPRX) is scheduled for June 9, 2021, at 3:50 p.m. EDT.

How can I access the webcasts of Royalty Pharma's investor conferences?

The webcasts can be accessed from Royalty Pharma’s ‘Events’ page on their website, and will be archived for a minimum of thirty days.

What role does Royalty Pharma play in the biopharmaceutical industry?

Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation and holding royalties on over 45 commercial products.

What products does Royalty Pharma hold royalties on?

Royalty Pharma holds royalties on products like Imbruvica, Xtandi, Tysabri, Trodelvy, Januvia, Promacta, and more.